Abbott completes acquisition of Evalve

2 November 2009

Your browser does not support inline frames or is currently configured not to display inline frames. Abbott (NYSE:ABT) has announced that it has completed its acquisition of Evalve, Inc., a developer of devices for minimally invasive repair of mitral valves.

Abbott acquired the remaining outstanding equity of Evalve that it did not already own for an upfront payment of $320 million, plus a $90 million payment if certain regulatory milestones are met.

The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease.

Evalve's minimally invasive catheter-based MitraClip system is the first commercially available treatment option approved in Europe for non-surgical mitral valve repair for patients suffering from the effects of mitral regurgitation — a condition that prevents the heart's mitral valve from closing completely. The MitraClip system is an investigational device in the United States and is currently in clinical trials.

"Evalve's innovative valve repair technology gives us the potential to provide new treatment options for millions of patients with mitral regurgitation around the world," said Robert Hance, senior vice president, vascular, Abbott. "This acquisition complements Abbott's industry-leading pipeline and strong vascular devices portfolio, which currently holds leadership positions in drug eluting and bare metal stent segments."

The acquisition of Evalve is one of six strategic acquisitions initiated by Abbott in the past 12 months to bolster long-term growth across its broad base of businesses through diversification of product portfolios, addition of new technology and expansion into key global emerging markets.

	Abbott completes acquisition of Evalve 2 November 2009 Your browser does not support inline frames or is currently configured not to display inline frames. Abbott (NYSE:ABT) has announced that it has completed its acquisition of Evalve, Inc., a developer of devices for minimally invasive repair of mitral valves. Abbott acquired the remaining outstanding equity of Evalve that it did not already own for an upfront payment of $320 million, plus a $90 million payment if certain regulatory milestones are met. The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease. Evalve's minimally invasive catheter-based MitraClip system is the first commercially available treatment option approved in Europe for non-surgical mitral valve repair for patients suffering from the effects of mitral regurgitation — a condition that prevents the heart's mitral valve from closing completely. The MitraClip system is an investigational device in the United States and is currently in clinical trials. "Evalve's innovative valve repair technology gives us the potential to provide new treatment options for millions of patients with mitral regurgitation around the world," said Robert Hance, senior vice president, vascular, Abbott. "This acquisition complements Abbott's industry-leading pipeline and strong vascular devices portfolio, which currently holds leadership positions in drug eluting and bare metal stent segments." The acquisition of Evalve is one of six strategic acquisitions initiated by Abbott in the past 12 months to bolster long-term growth across its broad base of businesses through diversification of product portfolios, addition of new technology and expansion into key global emerging markets. To top